The mission of the Barth Syndrome Foundation (BSF) is: Saving lives through education, advances in treatment, and finding a cure for Barth syndrome. In order to fulfill that mission the membership of BSF will necessarily have to be involved in clinical trials or clinical studies as they occur. BSF seeks to encourage voluntary participation in clinical trials by its membership in a general sense, but is prohibited from endorsing any particular trial or study. BSF will strive to provide as much information to its membership as it is able, and BSF will advertise the availability to voluntarily participate in clinical trials or studies as they occur. In the final analysis the decision to participate in clinical trials or studies is up to the individual or the individual’s parents/guardians.
ClinicalTrials.gov Identifier: NCT01629459
Status: Actively recruiting affected individuals, one year post transplant
Barth syndrome (BTHS) is a disorder that is characterized by heart failure, exercise intolerance and skeletal muscle weakness. Preliminary evidence demonstrates that endurance exercise training does not significantly improve exercise tolerance in BTHS. Because endurance exercise training targets a metabolic pathway that is adversely affected by BTHS, the investigators hypothesized that resistance training may improve exercise tolerance in BTHS because this type of training targets a different metabolic pathway than does endurance exercise. Therefore, the overall objective of the pilot/feasibility/proof-of-concept proposal is to collect preliminary data on the following hypothesis: Supervised resistance exercise training (3x/wk, 45min, 12 wks) will improve exercise tolerance, heart function, muscle strength and quality of life, and will be found safe in adolescents and young adults with BTHS.
William T Cade, PT, PhD (Telephone) 314-286-1432, email@example.com
Kathryn Bohnert, MS (Telephone) 314-362-2407, firstname.lastname@example.org
Affected Males’ Perspectives on Relationship-building and Family Planning Related to Barth syndrome
Institution: Boston University
Status: Actively recruiting
Led by Jason Shandler (Boston University) and in collaboration with Cindy James and Becky McCellan (Johns Hopkins Medical Instition) this study will involve an interview to discuss topics such as dating, relationships, family planning, support networks, and reproduction. Open to affected individuals 18 years and older, this study builds upon our efforts in hearing and communicating the patient’s voice to the broader research community. This study is actively recruiting and open to US and international-based individuals.
Contact Information: Jason Shandler email@example.com
Clinical Trials.gov Identifier: NCT03098797
Sponsor: Stealth BioTherapeutics
Status: Trial ongoing, fully recruited
The first ever clinical trial in Barth syndrome sponsored by Stealth BioTherapeutics and led by Hilary Vernon (JHMI) has completed the randomized control period – where individuals receive either drug or inactive treatment/placebo, then switched after 4 months – and is currently in open-label extension, where all trial participants know they are on drug. The trial began with 12 participants, and 8 individuals are currently participating in open-label extension. In October, we learned that the randomized control trial segment did not meet the original endpoints of improvements in the 6-minute walk test as well as other physiological measures, however, data analysis during the open-label extension found a 27% increase in average cardiac stroke volume, or the amount of blood pumped by the heart’s left ventricle per contraction. The open label extension involving 8 participants will continue with U.S. FDA review occurring later this year. Data analysis is ongoing, with results to be presented during the 2020 BSF Family, Science & Medicine Conference
Sponsor: University Hospitals Bristol NHS Foundation Trust
Status: Trial ongoing, fully recruited
Funding: National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme and the Barth Syndrome Foundation USA.
CARDIOMAN is currently assessing the impact of bezafibrate as a repurposed drug for Barth syndrome. Led by Guido Pieles and Colin Steward, this study is ongoing and conducted out of the Bristol Barth Clinic (UK). Following a similar randomized control process like TAZPOWER, bezafibrate or placebo is given to participants for 4 months, followed by a one month break, and then switched for the following 4 months. The trial will assess the effects of bezafibrate on blood cells, exercise capacity, heart function, and quality of life. Involving 18 individuals affected by Barth syndrome (6 years or older), this trial is fully recruited with the final tests conducted at the end of 2019. Data analysis is ongoing, with results to be presented during the 2020 BSF Family, Science & Medicine Conference. This trial was heavily guided by basic research funded by BSF and led by Zaza Khuchua (Cincinnati Children’s) and Mindong Ren (NYU).
Last updated 1/15/2020